NANO MRNA---Anti-aging therapy, signed a basic agreement with Yoshio Ikeda (Director of Tokyo Dermatology and Plastic Surgery).

On the 13th, NANOMRNA <4571> announced that it had signed a basic agreement regarding collaboration on new aesthetic medical treatments using mRNA with Dr. Yoshio Ikeda of Ikeda Dermatology and Plastic Surgery in Tokyo. Furthermore, this collaboration will be promoted through a subsidiary called "Nano Rejuvenation Co., Ltd." scheduled to be established in January 2025, and it will be clearly separated from the Pharmaceutical Business. Currently, several methods such as collagen injection are being considered for skin rejuvenation.

Fisco JapanDec 18 09:31

NANO mRNA --- Establishment of the subsidiary "Nano Rejuvenation" promoting aesthetic medicine.

NANO MRNA <4571> announced on the 13th the establishment of its subsidiary 'Nano Rejuvenation' focused on cosmetic medicine. The subsidiary will promote business development in the field of aesthetic medicine related to the research of skin anti-aging therapies using mRNA, which NANO MRNA has been advancing, and will clearly separate this from the Pharmaceutical Business.

Fisco JapanDec 17 15:38

Dream Arts, along with Classicom and others.

Below is the downward revision of VIS, with this period's operating profit and loss forecast at -0.214 billion yen, down from -0.144 billion yen. The approximately 0.268 billion yen gain from the sale of Nisso's subsidiary stocks is expected to be recorded as extraordinary profit. A revision of the performance forecast for Astroscale shows this period's project revenue forecast at 12 billion yen, down from 18 billion yen. A public tender offer by Shannon Innovation for Stock 3970 will be made at a price of 650 yen per share, and the listing is expected to be maintained after the public tender offer, with the remaining 25th new share rights.

Fisco JapanDec 16 06:30

NANO MRNA---Full-year financial estimates have been revised, with revenue up 111% compared to initial estimates, and the loss margin is expected to shrink.

NANO MRNA＜4571＞ announced its consolidated financial results for the second quarter of the fiscal year ending March 2025 (April-September 2024) on the 14th. Revenue decreased by 91.5% year-on-year to 0.007 billion yen, operating loss was 0.373 billion yen (compared to a loss of 0.518 billion yen), ordinary loss was 0.382 billion yen (compared to a loss of 0.471 billion yen), and net intermediate loss attributable to parent company shareholders was 0.518 billion yen (compared to a loss of 0.477 billion yen). Regarding the mRNA pharmaceutical pipeline, focusing on osteoarthritis of the knee, RUNX1.

Fisco JapanNov 19 09:45

Nano Mrna: Interim report

EDINETNov 18 14:32 · Announcements

Nano Mrna: Financial results briefing materials for the 2nd quarter (interim period) of the fiscal year ending March 31, 2025

JPXNov 15 12:00 · Announcements